Caseware UK (AP4) 2024.0.164 2024.0.164 2025-12-31 2025-12-31 The principal activity of the company throughout the period was the holding and operating of renewable energy projects.false 2024-09-11 false 2 The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.0 false true 15951458 2024-09-10 15951458 2024-09-11 2025-12-31 15951458 2023-09-11 2024-09-10 15951458 2025-12-31 15951458 c:Director1 2024-09-11 2025-12-31 15951458 c:Director2 2024-09-11 2025-12-31 15951458 d:CurrentFinancialInstruments 2025-12-31 15951458 d:Non-currentFinancialInstruments 2025-12-31 15951458 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 15951458 d:Non-currentFinancialInstruments d:AfterOneYear 2025-12-31 15951458 d:ShareCapital 2025-12-31 15951458 d:RetainedEarningsAccumulatedLosses 2025-12-31 15951458 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-12-31 15951458 c:OrdinaryShareClass1 2024-09-11 2025-12-31 15951458 c:OrdinaryShareClass1 2025-12-31 15951458 c:FRS102 2024-09-11 2025-12-31 15951458 c:AuditExempt-NoAccountantsReport 2024-09-11 2025-12-31 15951458 c:FullAccounts 2024-09-11 2025-12-31 15951458 c:PrivateLimitedCompanyLtd 2024-09-11 2025-12-31 15951458 2 2024-09-11 2025-12-31 15951458 6 2024-09-11 2025-12-31 15951458 e:Euro 2024-09-11 2025-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 15951458 ENLIGHT-NEWMED DEVELOPMENT (UK) LTD UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE PERIOD ENDED 31 DECEMBER 2025
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD CONTENTS
| Page
Balance Sheet | 1 - 2
Notes to the Financial Statements | 3 - 6
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD REGISTERED NUMBER: 15951458 BALANCE SHEET AS AT 31 DECEMBER 2025
|  | 2025
Note |  | €
Fixed assets |  |  |
Investments | 4 |  | 42,652
|  |  | 42,652
Current assets |  |  |
Debtors: amounts falling due after more than one year | 5 | 469,950 |
Cash at bank and in hand | 6 | 827,743 |
|  | 1,297,693 |
Creditors: amounts falling due within one year | 7 | (42,940) |
Net current assets |  |  | 1,254,753
Total assets less current liabilities |  |  | 1,297,405
Creditors: amounts falling due after more than one year | 8 |  | (1,348,362)
Net (liabilities)/assets |  |  | (50,957)
Capital and reserves |  |  |
Called up share capital | 10 |  | 118
Profit and loss account |  |  | (51,075)
|  |  | (50,957)
Page 1
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD REGISTERED NUMBER: 15951458 BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025 The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 8 July 2026.
H T Habusha | N Yehuda
Director | Director
The notes on pages 3 to 6 form part of these financial statements. Page 2
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2025
1. | General information
Enlight-Newmed Development (UK) Ltd is a private company, limited by shares, incorporated in England and Wales with registration number 15951458. The registered office is 32 St James's Street, 4th Floor, London, SW1A 1HD. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Going concern
The financial statements have been prepared on a going concern basis which assumes the company will continue in operational existence for the foreseeable future. In considering this, the directors have reviewed the implications of the ongoing world conflicts, the working capital requirements of the company and the support provided by its parent company for it to meet its liabilities, for a period of at least twelve months from the date of signing these financial statements.
| 2.3 | Foreign currency translation
Functional and presentation currency The company's functional and presentational currency is Euro. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
| 2.4 | Interest income
Interest income is recognised in profit or loss using the effective interest method. Page 3
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.5 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.6 | Valuation of investments
Investments in subsidiaries are measured at cost less accumulated impairment.
| 2.7 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.8 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
| 2.9 | Financial instruments
The company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.
3. | Employees
| The average monthly number of employees, including directors, during the period was 2.
4. | Fixed asset investments
|  | Investments in subsidiary companies
|  | €
| Cost |
| Additions | 42,652
| At 31 December 2025 | 42,652
Page 4
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2025
5. | Debtors
|  |  |  |  | 2025
|  |  |  |  | €
| Due after more than one year |
| Amounts owed by group undertakings | 469,832
| Called up share capital not paid | 118
|  | 469,950
6. | Cash and cash equivalents
|  |  |  |  | 2025
|  |  |  |  | €
| Cash at bank and in hand | 827,743
|  | 827,743
7. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025
|  |  |  |  | €
| Amounts owed to group undertakings | 21,326
| Accruals and deferred income | 21,614
|  | 42,940
8. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2025
|  |  |  |  | €
| Amounts owed to group undertakings | 1,348,362
|  | 1,348,362
Page 5
ENLIGHT-NEWMED DEVELOPMENT (UK) LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2025
9. | Financial instruments
|  |  |  |  | 2025
|  |  |  |  | €
| Financial assets |
| Cash at bank and in hand | 827,743
| Financial assets measured at fair value through profit or loss comprise of cash at bank and in hand.
10. | Share capital
|  |  |  |  | 2025
|  |  |  |  | €
|  | Allotted, called up and unpaid |
|  | 100 Ordinary shares of £1.00 each | 118
| On incorporation 100 shares were issued at par value at £1 (€1.18) each.
11. | Related party transactions
| Amounts owed by group undertakings (note 5), relates fully to an amount due from a subsidiary entity. This amount is unsecured, bears interest at the annual rate set by the Ministry of Finance in Morocco, and is not repayable until 11 August 2035. An additional amount of interest will be due upon financial closing of the project, but as the rate is yet to be agreed and the final balance subject to this interest is currently unknown, no further amounts have been accrued at this stage. Amounts owed to group undertakings due within one year (note 7) relates fully to the outstanding payment of the investment held in a subsidiary entity, due to a delay in the project. The project has commenced in 2026, when payment of this outstanding balance is due. Amounts owed to group undertakings due after more than one year (note 8), relates fully to an amount due to the company's immediate parent company (note 12). This amount is unsecured, bears interest at the rate set annually by the Ministry of Finance in Morocco, less 0.1%, and is not repayable until 11 August 2035.
12. | Controlling party
The company's immediate parent is Enlight-Newmed Development LP. The ultimate parent and controlling party is Enlight Renewable Energy Ltd (13 Ha'amal St., Afek Industrial Park, Rosh Ha'ayin 4809249), a company incorporated in Israel.
Page 6